Status:

TERMINATED

Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy

Lead Sponsor:

Mayo Clinic

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Anorexia

Weight Changes

Eligibility:

All Genders

Up to 21 years

Phase:

PHASE2

Brief Summary

RATIONALE: Megestrol acetate may help improve appetite and lessen weight loss caused by cancer. PURPOSE: This clinical trial studies megestrol acetate in treating weight loss or anorexia in young pati...

Detailed Description

PRIMARY OBJECTIVES:Proportion of Patients Who Maintain Weight or Experience Weight Gain. SECONDARY OBJECTIVES:BMI Trends, Caloric Intake, Weight Maintenance Over Time, Toxicity Profile as Assessed by...

Eligibility Criteria

Inclusion

  • Any pediatric patient with an underlying diagnosis of a malignancy (excluding hematological malignancies like leukemias and lymphomas)
  • ≥5% weight loss from diagnosis of primary malignancy (must be currently on chemotherapy and/or radiation therapy or scheduled to receive cancer therapy OR ≥5% weight loss following bone marrow transplant (autologous or allogeneic blood/bone marrow) and not actively receiving corticosteroid therapy
  • Negative pregnancy test done =\< 7 days prior to registration for women of childbearing potential only

Exclusion

  • Receiving tube feedings or parenteral nutrition
  • Evidence of ascites
  • Current (within the past 28 days) or planned treatment with adrenal steroids (short-term use of dexamethasone around days of intravenous chemotherapy is allowed for protection against emesis), androgens, progestational agents, or appetite stimulants (e.g., dronabinol)
  • Known mechanical obstruction of the alimentary tract, malabsorption, or intractable vomiting (\> 5 episodes/week)
  • History of unresectable brain tumor or cancer metastatic to the brain
  • History of thromboembolic disease
  • Insulin-requiring diabetes
  • Congestive heart failure and/or uncontrolled hypertension
  • Anticoagulation
  • Previous history of thrombosis (personal and immediate family)
  • Concurrent corticosteroid therapy (except as an antiemetic)

Key Trial Info

Start Date :

March 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2012

Estimated Enrollment :

1 Patients enrolled

Trial Details

Trial ID

NCT01200602

Start Date

March 1 2011

End Date

January 1 2012

Last Update

November 25 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mayo Clinic

Rochester, Minnesota, United States, 55905